Prehypertension and the cardiometabolic syndrome: targeting several risk factors to achieve maximum benefit

References

• Duprez D, Toleuova A. Prehypertension and the cardiometabolic syndrome: pathological and clinical consequences. Expert Rev Cardiovasc Ther 2013;11(12):1725-33
   PubMedGoogle Scholar
• Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5
   PubMed Web of Science ®Google Scholar
• Faselis C, Doumas M, Kokkinos JP, et al. Exercise capacity and progression from prehypertension to hypertension. Hypertension 2012;60:333-8
   PubMed Web of Science ®Google Scholar
• Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview. Curr Vasc Pharmacol 2013. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Nikolic D, Katsiki N, Montalto G, et al. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients 2013;5:928-48
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 2011;9:531-2
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011;9:533-71
   PubMed Web of Science ®Google Scholar
• Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, et al. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012;51:314-24
   PubMed Web of Science ®Google Scholar
• Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008;23:370-8
   PubMed Web of Science ®Google Scholar
• Mihas C, Kolovou GD, Mikhailidis DP, et al. Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis. Curr Vasc Pharmacol 2011;9:271-80
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011;9:258-70
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Mikhailidis DP, Nordestgaard BG, et al. Definition of postprandial lipaemia. Curr Vasc Pharmacol 2011;9:292-301
   PubMed Web of Science ®Google Scholar
• Rizzo M, Obradovic M, Labudovic-Borovic M, et al. Uric acid metabolism in pre-hypertension and the metabolic syndrome. Curr Vasc Pharmacol 2013. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Katsiki N, Karagiannis A, Athyros VG, Mikhailidis DP. Hyperuricaemia: more than just a cause of gout? J Cardiovasc Med (Hagerstown) 2013;14:397-402
   PubMed Web of Science ®Google Scholar
• Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol 2011;9:698-705
   PubMed Web of Science ®Google Scholar
• Bhatia LS, Curzen NP, Byrne CD. Nonalcoholic fatty liver disease and vascular risk. Curr Opin Cardiol 2012;27:420-8
   PubMed Web of Science ®Google Scholar
• Tomiyama H, Yamashina A. Arterial stiffness in prehypertension: a possible vicious cycle. J Cardiovasc Transl Res 2012;5:280-6
   PubMed Web of Science ®Google Scholar
• Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Metabolic syndrome and non-cardiac vascular diseases: an update from human studies. Curr Pharm Des 2013. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007;22:118-27
   PubMed Web of Science ®Google Scholar
• Athyros VG, Karagiannis A, Ganotakis ES, et al. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT) collaborative group. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin 2011;27:1659-68
   PubMed Web of Science ®Google Scholar
• Athyros VG, Giouleme O, Ganotakis ES, et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 2011;7:796-805
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Gossios TD, et al. GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916-22
   PubMed Web of Science ®Google Scholar